Skip to content

Research at St Andrews

Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label phase II clinical trial (SAEFRIF)

Research output: Contribution to journalArticlepeer-review

Author(s)

Ruth Nabisere, Joseph Musaazi, Paolo Denti, Florence Aber, Mohammed Lamorde, Kelly E. Dooley, Rob Aarnoutse, Derek James Sloan, Christine Sekaggya-Wiltshire

School/Research organisations

Abstract

Background Tuberculosis (TB) is a significant public health problem that causes substantial morbidity and mortality. Current first-line anti-TB chemotherapy, although very effective, has limitations including long-treatment duration with a possibility of non-adherence, drug interactions, and toxicities. Dose escalation of rifampicin, an important drug within the regimen, has been proposed as a potential route to higher treatment efficacy with shorter duration and some studies have suggested that dose escalation is safe; however, these have almost entirely been conducted among human immunodeficiency (HIV)-negative TB patients. TB-HIV co-infected patients on antiretroviral therapy (ART) are at increased risk of drug-drug interactions and drug-related toxicities. This study aims to determine the safety of higher doses of rifampicin and its effect on the pharmacokinetics of efavirenz (EFV) and dolutegravir (DTG) in TB-HIV co-infected patients.

Methods This study is a randomized, open-label, phase IIb clinical trial among TB-HIV infected adult outpatients attending an HIV clinic in Kampala, Uganda. Patients newly diagnosed with TB will be randomized to either standard-dose or high-dose rifampicin (35 mg/kg) alongside standard TB treatment. ART-naïve patients will be randomly assigned to first-line ART regimens (DTG or EFV). Those who are already on ART (DTG or EFV) at enrollment will be continued on the same ART regimen but with dose adjustment of DTG to twice daily dosing. Participants will be followed every 2 weeks with assessment for toxicities at each visit and measurement of drug concentrations at week 6. At the end of intensive-phase therapy (8 weeks), all participants will be initiated on continuation-phase treatment using standard-dose rifampicin and isoniazid.

Discussion This study should avail us with evidence about the effect of higher doses of rifampicin on the pharmacokinetics of EFV and DTG among TB-HIV co-infected patients. The trial should also help us to understand safety concerns of high-dose rifampicin among this vulnerable cohort.

Trial registration ClinicalTrials.gov, ID: NCT03982277. Registered retrospectively on 11 June 2019.
Close

Details

Original languageEnglish
Article number181
Number of pages9
JournalTrials
Volume21
DOIs
Publication statusPublished - 13 Feb 2020

    Research areas

  • Rifamycins, Antiretrovirals, HIV, Pharmacokinetics, Tuberculosis

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Population pharmacokinetics and Bayesian dose adjustment to advance TDM of anti-TB drugs

    Sturkenboom, M. G. G., Märtson, A-G., Svensson, E. M., Sloan, D. J., Dooley, K. E., van den Elsen, S. H. J., Denti, P., Peloquin, C. A., Aarnoutse, R. E. & Alffenaar, J-W. C., 6 Mar 2021, In: Clinical Pharmacokinetics. 26 p.

    Research output: Contribution to journalReview articlepeer-review

  2. Co-prevalent infections in adults with HIV-associated cryptococcal meningitis are associated with an increased risk of death: a nested analysis of the Advancing Cryptococcal meningitis Treatment for Africa (ACTA) cohort [version 1; peer review: awaiting peer review]

    Ellis, J., Kalata, N., Dziwani, E., Matope, A., Wang, D., Molloy, S. F., Harrison, T. S., Lalloo, D. G., Sloan, D. J. & Heyderman, R. S., 1 Feb 2021, In: Wellcome Open Research.

    Research output: Contribution to journalArticlepeer-review

  3. MicroRNA-122 and cytokeratin-18 have potential as a biomarkers of drug-induced liver injury in European and African patients on treatment for mycobacterial infection

    Rupprechter, S. A. E., Sloan, D. J., Oosthuyzen, W., Bachmann, T. T., Hill, A. T., Dhaliwal, K., Templeton, K., Matovu, J., Sekaggya-Wiltshire, C. & Dear, J. W., 26 Jan 2021, (E-pub ahead of print) In: British Journal of Clinical Pharmacology. Early View, 12 p.

    Research output: Contribution to journalArticlepeer-review

  4. Molecular detection of mycobacterium tuberculosis in oral mucosa from patients with presumptive tuberculosis

    Molina-Moya, B., Ciobanu, N., Hernandez, M., Prat-Aymerich, C., Crudu, V., Adams, E. R., Codreanu, A., Sloan, D. J., Cuevas, L. E. & Dominguez, J., 21 Dec 2020, In: Journal of Clinical Medicine. 9, 12, 7 p., 4124.

    Research output: Contribution to journalArticlepeer-review

Related by journal

  1. Trial Forge Guidance 2: how to decide if a further Study Within A Trial (SWAT) is needed

    Treweek, S., Bevan, S., Bower, P., Briel, M., Campbell, M., Christie, J., Collett, C., Cotton, S., Devane, D., El Feky, A., Galvin, S., Gardner, H., Gillies, K., Hood, K., Jansen, J., Littleford, R., Parker, A., Ramsay, C., Restrup, L., Sullivan, F. & 7 others, Torgerson, D., Tremain, L., von Elm, E., Westmore, M., Williams, H., Williamson, P. R. & Clarke, M., 7 Jan 2020, In: Trials. 21, 9 p., 33.

    Research output: Contribution to journalArticlepeer-review

  2. Factors associated with recruitment to randomised controlled trials in general practice: protocol for a systematic review

    Moffat, K. R., Cannon, P., Shi, W. & Sullivan, F., 10 May 2019, In: Trials. 20, 4 p., 66.

    Research output: Contribution to journalArticlepeer-review

  3. The effect of optimised patient information materials on recruitment in a lung cancer screening trial: an embedded randomised recruitment trial

    Parker, A., Knapp, P., Treweek, S., Madhurasinghe, V., Littleford, R., Gallant, S., Sullivan, F., Schembri, S., Rick, J., Graffy, J., Collier, D. J., Eldridge, S., Kennedy, A. & Bower, P., 18 Sep 2018, In: Trials. 19

    Research output: Contribution to journalArticlepeer-review

  4. Trial Forge Guidance 1: what is a Study Within A Trial (SWAT)?

    Treweek, S., Bevan, S., Bower, P., Campbell, M., Christie, J., Clarke, M., Collett, C., Cotton, S., Devane, D., El Feky, A., Flemyng, E., Galvin, S., Gardner, H., Gillies, K., Jansen, J., Littleford, R., Parker, A., Ramsay, C., Restrup, L., Sullivan, F. & 4 others, Torgerson, D., Tremain, L., Westmore, M. & Williamson, P. R., 23 Feb 2018, In: Trials. 19, 5 p., 139.

    Research output: Contribution to journalArticlepeer-review

ID: 266337553

Top